The global kidney cancer drugs market size to be valued at USD 6.3 billion by 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% during the forecast period. The U.S. dominated the scene among the seven major markets. Market growth is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rise in the incidence of renal cancer due to the growing geriatric population and more prominent smoking habits.
Kidney cancer accounts for 2.0% of total adult malignancies globally and makes up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma accounts for over 90.0% of all kidney cancers while renal pelvis cancer makes up for <10.0% of microscopically confirmed kidney carcinomas. Clear cell renal cell carcinoma is the most prevalent subtype of renal cell carcinoma, affecting 70.0% of patients with RCC.
The incidence rate of RCC is highest in North America and Western Europe. Metastatic RCC is present in around 30.0% of patients at the time of diagnosis. Globally, approximately 270,000 new cases are diagnosed every year and around 116,000 deaths per year are due to renal cell carcinoma.
Cancer has become the second largest cause of death globally, after cardiovascular diseases. External factors such as smoking, changing food patterns, urbanization, and prolonged post-reproductive life contribute to cancer. As a result, the rising prevalence of kidney cancer is predicted to drive the demand for kidney cancer medications in the forecast period.
The growth in the aging population and the increasing frequency of kidney cancer patients are the factors driving market expansion. Although there are several therapeutic options available, researchers have shifted their focus on medicines and immunotherapies. Therefore, in the projection period, the market is expected to increase further through robust pipeline and developing treatments.
The lack of suitable regulatory requirements for medication prescriptions and preference for cost-effective generic renal cancer treatments is likely to obstruct the global market for drugs. Furthermore, the drugs destroying the cancer cells proves harmful for healthy cells in the body. This causes a number of side effects in patients, the most prevalent of which are gastrointestinal issues, hair loss, exhaustion, and skin diseases. As a result, the market's expansion is being hampered by the disadvantages associated with kidney cancer medications.
Immunotherapies pose a lucrative avenue for kidney cancer treatment. Moreover, in future, the developing regions with a large undiagnosed patient population are expected to attract market opportunities for manufacturers.
Until the 1980s, treatment of kidney cancer included surgical removal of the kidneys, which later progressed to laparoscopic removal of the tumor-affected part. Drugs are usually given to advanced-stage patients with disease progression. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.
Rising preference for novel immunotherapies and immune-oncologic agents will push the use of targeted therapies to specific patient subpopulations or later lines of treatment. Programmed death-1 (PD-1) inhibitors are poised to displace TKIs and mTOR inhibitors as the standard of care in first-and second-line RCC settings. Combination regimens, specifically those including PD-1 inhibitors will be introduced in the first-line setting to target major unmet needs, including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life.
As kidney cancer is not responsive to traditional cancer treatments, drug development for this disease focuses on using novel treatments. Novel agents have expanded opportunities in the kidney cancer drugs market through a larger number of patients under treatment and better treatment prospects compared to traditional therapies. Some prominent players covered in the segment are Amgen/Allergan, Argos Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, and Roche.
PD-1 and PD-L1 inhibitors represent a paradigm shift in kidney cancer treatment. Several PD-1 and PD-L1 agents with novel MoAs are in early development and are being evaluated both as monotherapy and in combination with already approved immuno-oncology agents. The notable clinical profile of immuno-oncology drugs is reflected in their rapid uptake and expansion of indications.
The U.S. led the market with a share of more than 35.0% in 2016. Increased adoption of therapeutics, established healthcare infrastructure, and the presence of key manufacturers in the country are major factors responsible for its large share. Japan is expected to experience a high growth rate owing to various factors such as multiple product launches in the region during the forecast period and the existence of a large geriatric population base susceptible to kidney cancer.
China offers strong opportunities for market expansion due to the ongoing Healthy China 2020 healthcare reform and the removal of price caps on all medicine categories. The Chinese government has initiated a supportive 12th Five-Year Plan measures targeting biotechnology as a crucial development sector. Additionally, the presence of a large target base with strong unmet clinical needs is expected to drive regional market growth.
Major companies operating in this market include Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech (Roche), Novartis, Pfizer, and Prometheus Labs. These companies are focusing on product development through clinical collaborations and commercial expansion in emerging markets.
Biosimilar development is gaining traction as a promising market opportunity in kidney cancer therapeutics. Several biotech companies have already launched their Avastin biosimilars across several cancer indications in emerging markets such as India, Russia, and Argentina.
In December 2022, Exelixis, Inc., an oncology-focused biotechnology company, announced the initiation of the STELLAR-304. It is a phase-3 pivotal trial evaluating zanzalintinib with nivolumab versus sunitinib in patients having advanced non-clear cell kidney cancer.
In February 2022, Eisai Co., Ltd. and Merck & Co., Inc., Rahway, NJ, USA announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA by Eisai plus KEYTRUDA by Merck & Co., Inc. for radically unresectable or metastatic renal cell carcinoma, the most common type of kidney cancer.
Revenue forecast in 2022
USD 6.3 billion
CAGR of 5.4% from 2016 to 2022
Base year for estimation
2016 - 2022
Revenue in USD billion/million and CAGR from 2016 to 2022
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Therapeutic class, pharmacologic class, country
The U.S.; The U.K.; Germany; Spain; Italy; France; Japan
Key companies profiled
Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech (Roche); Novartis; Pfizer; Prometheus Labs.
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2022. For the purpose of this report, Grand View Research has segmented the global kidney cancer drugs market report on the basis of therapeutic class, pharmacologic class, and country:
Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)
Pharmacologic Class Outlook (Revenue, USD Million, 2016 - 2022)
Cytokine Immunotherapy (IL-2)
Country Outlook (Revenue, USD Million, 2016 - 2022)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."